drugset
drugset / Trial / NCT04676893

Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects

NCT04676893 ↗

Phase 1 Unknown 56 enrolled Chong Kun Dang Pharmaceutical
RandomizedCrossoverOpen-labelTreatment

Summary

This study is an open-label, randomized, single dose, crossover study to evaluate the pharmacokinetics, safety and tolerability of CKD-388 in healthy subjects

Timeline

Start
2021-02-26
Primary completion
2021-05-11
Completion
2021-05-18

Drugs

EvaluationDrugModalityDoseRoute
Subject CKD-388 Unknown — —
Subject D418 Unknown — —

Indications

chronic hepatitis B virus infection